EUVIMEDEUVIMED entdecken
Editorial

Adoption of Artificial Intelligence–Based End Points — A New Era for Clinical Trials

Kushal T Kadakia iD, Harlan M Krumholz iD

NEJM AI · 25.06.2026 · 3 (7)

DOI: 10.1056/aip2501235 ↗

Kurz gefasst

Editorial in der Zeitschrift NEJM AI, erschienen am 25.06.2026. Verfasst von Kushal T Kadakia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Clinical Trials as Topic, Drug Development, Endpoint Determination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractEnd point evaluation is central to the evidence generation process in a clinical trial, and artificial intelligence (AI) tools have the potential to improve the efficiency and accuracy of this process. In 2025, the European Medicines Agency and U.S. Food and Drug Administration independently endorsed AIM-NASH, an AI-based tool for histologic assessment in clinical trials for metabolic dysfunction-associated steatohepatitis. As the first ever regulatory certification of an AI-enabled end point, this represents a milestone for the emerging development and use of AI tools for drug development. This article examines the evidence and policy decisions underlying the endorsement and explores the clinical and regulatory implications of AI-enabled end points for the transformation of clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceClinical Trials as TopicDrug DevelopmentEndpoint DeterminationNon-alcoholic Fatty Liver DiseaseHumansUnited StatesUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA.
  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.

ORCID-Profile: Kushal T Kadakia, Harlan M Krumholz

Zitieren

APA

Kadakia, K. T., & Krumholz, H. M. (2026). Adoption of Artificial Intelligence–Based End Points — A New Era for Clinical Trials. NEJM AI, 3(7). https://doi.org/10.1056/aip2501235

Vancouver

Kadakia KT, Krumholz HM. Adoption of Artificial Intelligence–Based End Points — A New Era for Clinical Trials. NEJM AI. 2026;3(7). doi:10.1056/aip2501235

BibTeX
@article{Kadakia2026,
  author = {Kadakia, Kushal T and Krumholz, Harlan M},
  title = {Adoption of Artificial Intelligence–Based End Points — A New Era for Clinical Trials},
  journal = {NEJM AI},
  year = {2026},
  volume = {3},
  number = {7},
  doi = {10.1056/aip2501235}
}
Kostenlos starten →